



US009511048B2

(12) **United States Patent**  
**Hwang et al.**

(10) **Patent No.:** **US 9,511,048 B2**  
(45) **Date of Patent:** **Dec. 6, 2016**

(54) **USE OF FLAVONE COMPOUND FOR PREVENTION OR TREATMENT OF OBESITY**

(71) Applicant: **INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY**, Seoul (KR)

(72) Inventors: **Jae-Kwan Hwang**, Goyang-si (KR); **Myung Suk Kim**, Seoul (KR); **Ga Hui Oh**, Seoul (KR)

(73) Assignee: **Industry-Academic Cooperation Foundation, Yonsei University**, Seoul (KR)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/541,389**

(22) Filed: **Mar. 4, 2015**

(65) **Prior Publication Data**

US 2015/0209324 A1 Jul. 30, 2015

#### **Related U.S. Application Data**

(63) Continuation of application No. PCT/KR2013/004375, filed on May 16, 2013.

(30) **Foreign Application Priority Data**

May 16, 2012 (KR) ..... 10-2012-0051779

(51) **Int. Cl.**

**A61K 31/353** (2006.01)

**A61K 31/352** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/353** (2013.01); **A23K 20/111** (2016.05); **A23K 20/121** (2016.05); **A23L 33/105** (2016.08); **A23L 33/30** (2016.08); **A61K 31/352** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

#### **FOREIGN PATENT DOCUMENTS**

KR 10-2008-0113326 12/2008

#### **OTHER PUBLICATIONS**

Azuma, Toshiaki. Antimutagenic and  $\alpha$ -glucosidase inhibitory effects of constituents from Kaempferia parviflora. Food Chemistry. 125 (2011) 471-475.\*

Hollander, et al., Acarbose in the Treatment of Type I Diabetes, Diabetes Care, Mar. 1997, vol. 20, Issue 3, pp. 248-253.

Hollander, Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes, Diabetes Spectrum, vol. 20, Issue 3, pp. 159-165.

Azuma, et al., "Antimutagenic and  $\alpha$ -glucosidase inhibitory effects of constituents from Kaempferia parviflora", Elsevier, 2011, vol. 55, pp. 471-475.

Panthong, et al., "Anti-Inflammatory Activity of 5, 7-Dimethoxyflavone", Planta Medica, 1989, pp. 133-136.

Bjorn Richelsen, "Prostaglandin E 2 Action and Binding in Human Adipocytes: Effects of Sex, Age, and Obesity, Metabolism", 1988, pp. 268-275, vol. 37 No. 3.

Akase et al., "Antiobesity effects of Kaempferia parviflora in spontaneously obese type II diabetic mice", Journal of Natural Medicine, 2011, vol. 65, pp. 73-80.

Tsuji, et al., "Accumulation and metabolism of the anticancer flaconoid 5, 7-dimethoxyflavone compared to its unmethylated analog chrysin in the Atlantic killifish", Chemico-Biological interactions, 2006, vol. 164, pp. 85-92.

Peter G. Kopelman, "Obesity as a medical problem", Nature, Apr. 6, 2000, pp. 635-643, vol. 404.

Ng, et al., "The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian Gulf States", obesity reviews, international assoc. for the study of obesity, 2010 vol. 12, pp. 1-13.

Lai, et al., "Xanthigen Suppresses Preadipocyte Differentiation and Adipogenesis through Down-regulation of PPAR and C/EBPs and Modulation of SIRT-1, AMPK, and FoxO Pathways", Journal of Agricultural and Food Chemistry, 2012, pp. 1094-1101.

Sohle, et al., "White Tea extract induces lipolytic activity and inhibits adipogenesis in human subcutaneous (pre)-adipocytes", Nutrition & Metabolism, 2009, vol. 6:20, pp. 1-10.

Duncan, "Peroxisome Proliferator Activated Receptor-Alpha (PPAR $\alpha$ ) and PPAR Gamma Coactivator-1alpha (PGC-1 $\alpha$ ) Regulation of Cardiac Metabolism in Diabetes", NIH Public Access, Mar. 2011, pp. 1-10.

Jong Won Yun, "Possible anti-obesity therapeutics from nature—A review", Elsevier, 2010, Phytochemistry 71, pp. 1625-1641.

Sae-Wong, et al., "Anti-inflammatory mechanism of Kaempferia parviflora in murine macrophage cells (RAW 264.7) and in experimental animals", Elsevier, 2009, Journal of Ethnopharmacology 124, pp. 576-580.

Mahaboob S. Khan, et al., "Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF- $\kappa$ B signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model", Elsevier, 2011, Chemico-Biological Interactions 193, pp. 12-21.

(Continued)

*Primary Examiner* — Samantha Shterengarts

(74) *Attorney, Agent, or Firm* — H.C. Park & Associates, PLC

(57) **ABSTRACT**

The present invention relates to a pharmaceutical composition containing flavone compound as an active ingredient for treating obesity, and more specifically to a pharmaceutical composition for preventing or treating obesity and a dietary composition for preventing or reducing obesity containing 5,7-dimethoxyflavone or 5,7,4'-trimethoxyflavone. The compound according to the present invention inhibits adipogenesis, and reduces expression of the key transcription factors (SREBP1c and C/EBP) related to lipogenesis and of enzyme proteins (FAS and ACC) related to adipogenesis, and thus is effective in preventing or treating obesity.

**3 Claims, 3 Drawing Sheets**